Skip to content
AI IntelligenceAug 24, 2026AI Intelligence
Article

The FDA cleared C2N Diagnostics' PrecivityAD2 blood test, developed from Washington University technology, to aid Alzheimer's...

Diagnosis by detecting amyloid plaques. This marks a step toward accessible early detection.

Data Cube AI EditorialSource: Hacker News
01

Source Brief

The FDA cleared C2N Diagnostics' PrecivityAD2 blood test, developed from Washington University technology, to aid Alzheimer's diagnosis by detecting amyloid plaques. This marks a step toward accessible early detection.